-
ML133 HCl for Kir2.1 PASMC Research
2026-09-08
ML133 HCl is a selective potassium channel inhibitor for connecting Kir2.1 activity with pulmonary artery smooth muscle cell behavior. This workflow-focused guide covers solution preparation, PDGF-BB challenge design, orthogonal migration and signaling assays, and troubleshooting for reproducible cardiovascular ion channel research.
-
Merbromin Inhibits SARS-CoV-2 3CLpro
2026-09-08
Chen et al. identified merbromin as a selective mixed-type inhibitor of the SARS-CoV-2 main protease, 3CLpro, through biochemical screening, enzyme kinetics, surface plasmon resonance, and molecular docking. The study is notable because it distinguishes inhibition of 3CLpro from effects on other proteases, offering a mechanistic starting point for coronavirus protease inhibitor design.
-
Azathramycin A in Tuberculosis Research Workflows
2026-09-07
Azathramycin A combines ribosome-focused antibacterial activity with value as a stability and degradation-study analyte. This guide shows how to build solvent-aware binding, protein synthesis, PK/PD-inspired, and antibiotic resistance research workflows without overextending evidence from unrelated animal models.
-
Sulfo-NHS-SS-Biotin for Cleavable Protein Workflows
2026-09-07
Sulfo-NHS-SS-Biotin combines non-permeating cell-surface labeling with a reducible disulfide spacer, making it useful for affinity enrichment, trafficking studies, and reversible protein purification. Its application to Cx43 and lysosomal quality-control research provides a practical way to separate surface-accessible proteins from total cellular pools.
-
CAF–ANGPTL4–IQGAP1 Signaling in Prostate Cancer
2026-09-05
This reference study identifies a cancer-associated fibroblast mechanism that links paracrine ANGPTL4 signaling to IQGAP1, mitochondrial biogenesis, oxidative phosphorylation, and reduced chemotherapy sensitivity in prostate cancer. Its combination of secretome proteomics, metabolic analysis, interaction assays, and inhibitor screening provides a framework for studying tumor microenvironment-driven drug resistance.
-
DAPT (GSI-IX) Workflow for Notch Signaling Studies
2026-09-04
DAPT (GSI-IX) provides a rapid chemical route to perturb γ-secretase-dependent APP and Notch processing in cell, tissue-engineering, and disease-model workflows. Its most useful application is not simply pathway inhibition, but pairing a controlled dose matrix with lineage, proliferation, and substrate-specific readouts.
-
EPI-001: Rethinking AR N-Terminal Inhibition
2026-09-04
EPI-001 is an androgen receptor N-terminal domain inhibitor designed to interrogate ligand-dependent and ligand-independent AR signaling. This thought-leadership guide connects prostate cancer and TNBC evidence with practical assay design, biomarker strategy, and translational decision-making.
-
Proteinase K as an Orthogonal Protease Assay Control
2026-09-03
Proteinase K is more than a genomic DNA isolation enzyme: its broad cleavage profile can help researchers design orthogonal protease controls and interpret inhibitor assays. This article connects its biochemical behavior with the merbromin–SARS-CoV-2 3CLpro study while defining practical limits for DNA and enzymology workflows.
-
Spiroplasma eriocheiris Entry into Drosophila S2 Cells
2026-09-03
Wei and colleagues established a Drosophila Schneider 2 cell model showing that Spiroplasma eriocheiris enters host cells through clathrin-dependent endocytosis and macropinocytosis. The study further connects intracellular infection with actin filaments and microtubules, providing a useful framework for interpreting cytoskeletal perturbation in invertebrate host–pathogen systems.
-
ARCA EGFP mRNA (5-moUTP) Assay Guide
2026-09-02
ARCA EGFP mRNA (5-moUTP) is a polyadenylated mRNA reporter for direct EGFP detection after mRNA transfection in mammalian cells. Its ARCA cap, 5-moUTP modification, and optimized poly(A) tail are designed to improve translation consistency, transcript stability, and fluorescence-based assay reproducibility.
-
Etomoxir: From FAO Blockade to Translational Insight
2026-09-02
Etomoxir is more than a CPT-1 inhibitor: it is a strategic metabolic perturbation tool for connecting fatty acid oxidation, immune-cell function, lipid remodeling, and disease phenotypes. This thought-leadership guide shows how to deploy R-(+)-Etomoxir in standardized whole-blood, cellular, and EAE workflows while accounting for DGAT activity, irreversible inhibition, donor variability, and translational limitations.
-
Z-VDVAD-FMK: A Causal Probe of Viral Apoptosis
2026-09-01
Z-VDVAD-FMK can turn caspase inhibition into a causal test of apoptosis during Senecavirus A infection. This article explains how to combine the inhibitor with DDX23, viral-protein, and cell-death readouts while avoiding overinterpretation of caspase specificity.
-
METTL16–SENP3–LTF Axis in HCC Ferroptosis
2026-09-01
Wang et al. identify METTL16 as an m6A-linked suppressor of ferroptosis in hepatocellular carcinoma and define a METTL16–SENP3–LTF pathway that limits iron-dependent lipid peroxidation. By combining molecular assays, organoids, xenografts, genetically modified mice, and human samples, the study provides a mechanistic basis for investigating ferroptosis sensitization in HCC, while clinical translation remains prospective.
-
Brefeldin A: From Trafficking to Assay Design
2026-08-31
Brefeldin A is a versatile trafficking perturbant for connecting ER–Golgi disruption with ER stress, cancer-cell phenotypes, and endothelial-barrier assay design. This article translates findings on moesin-dependent endothelial injury into a rigorous framework for interpreting BFA experiments without overstating cross-domain evidence.
-
VX-765 and the Logic of Separating Cell Death
2026-08-31
Translational inflammation research increasingly depends on distinguishing inflammatory pyroptosis from transcription-linked apoptosis. This article examines how VX-765 and its active metabolite VRT-043198 can help researchers isolate caspase-1 biology while using recent RNA Pol II findings to sharpen experimental interpretation.